Active Pharmaceutical Ingredients (API) Market – Industry Analysis and Forecast (2019-2027)_by Synthesis Type (Biotech, Synthetic), by Drug Type (Branded/Innovative Drugs, Generic Drugs, Over-the-counter Drugs), by Manufacturer Type (Captive Manufacturers, Merchant Manufacturers), by Therapeutic Area (Cardiology, Pulmonology, Oncology, Neurology, Ophthalmology, Orthopedics), and by Geography

Active Pharmaceutical Ingredients (API) Market – Industry Analysis and Forecast (2019-2027)_by Synthesis Type (Biotech, Synthetic), by Drug Type (Branded/Innovative Drugs, Generic Drugs, Over-the-counter Drugs), by Manufacturer Type (Captive Manufacturers, Merchant Manufacturers), by Therapeutic Area (Cardiology, Pulmonology, Oncology, Neurology, Ophthalmology, Orthopedics), and by Geography

Market Scenario

Active Pharmaceutical Ingredients (API) market size was valued at USD 179.77 billion in 2019 and is projected to reach to USD XX billion by 2027 at a CAGR of XX %. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. This is a comprehensive global report focused on the current and future prospects of the active pharmaceutical ingredients market. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and microenvironmental factors. An in-depth analysis of past trends, future trends, demographics, and technological advancements for the active pharmaceutical ingredients market has been done in order to calculate the growth rates for each segment and sub-segments. An active pharmaceutical ingredient is a biologically active portion of a pharmaceutical drug intended to perform certain pharmacological actions or have prominent effects for the diagnosis, cure, treatment or prevention of chronic and acute diseases. The rising prevalence of chronic diseases and increasing uptake of biopharmaceuticals is expected to majorly drive the market growth. As per data published by the World Health Organization (WHO), chronic disease prevalence is anticipated to rise by 57.0% by the year 2020. The number of people suffering from diabetes in developing countries was 84.0 million in 1995, which is projected to increase by 2.5-fold to 228.0 million in 2025. Chronic diseases include diabetes, obesity, and cardiovascular diseases, cancer, neurological diseases, and other diseases; the rise in prevalence of these diseases are augmenting the demand for treatment that may support the market growth over the forecast period. Furthermore, augmented demand for rapid-acting & efficient drugs and the emergence of innovative drug manufacturing facilities are expected to assist in market growth during the forecast period. Loss of drug exclusivity is impeding the revenue growth! Patent expiration is accountable for the huge loss for pharmaceutical firms in terms of revenue, which is anticipated to impede the market growth during the forecast period. The biotech APIs segment is expected to witness significant market growth. The biotech APIs segment is expected to register comparatively higher CAGR over thee forecast period owing to high R&D for novel biosimilar drugs, escalating demand for protein-based therapeutics, and rising key traditional manufacturers’ focus toward biological drugs. The branded/innovative drugs segment spearheaded the market. A surge in prescription rates and drug prices coupled with higher spending on R&D activities are expected to contribute to the dominance of the branded/innovative drugs segment. The merchant manufacturers segment is expected to witness lucrative market growth. Worldwide rising outsourcing of API/drug molecule formulation from drug manufacturers in order to eliminate the need for heavy investment in manufacturing processes. North America is expected to hold a major chunk of the market during the forecast period. North America is anticipated to hold substantial market share over next ten years owing to the presence of favorable government initiatives, changing lifestyle leads to the development of diseases, rising investment on R&D, and technological developments in drug manufacturing processes. Key Highlights: • Active pharmaceutical ingredients market size analysis and forecast • Comprehensive study and analysis of market drivers, restraints, and opportunities influencing the growth of the active pharmaceutical ingredients market • Active pharmaceutical ingredients market segmentation on the basis of synthesis type, drug type, manufacturer type, therapeutic area, and geography (regional) • Active pharmaceutical ingredients market strategic analysis with respect to individual growth trends, future prospects along with a contribution of various sub-market stakeholders have been considered under the scope of a study • Active pharmaceutical ingredients market analysis and forecast for five major regions such as North America, Europe, Asia Pacific, Latin America, and MEA. • Profiling of key industry players, their strategic perspective, market positioning and analysis of core competencies • Competitive landscape of the key players operating in the active pharmaceutical ingredients market including competitive developments, investments, and strategic expansion Years that have been considered for the study are as follows: • Base Year – 2018 • Estimated Year – 2019 • Forecast Period – 2019 to 2026 For company profiles, 2018 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered. Research Methodology: The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at the market value for active pharmaceutical ingredients market. Some of the key players of the active pharmaceutical ingredients market include: • AbbVie Inc. • Bristol-Myers Squibb Company • Boehringer Ingelheim GmbH • Cipla Inc. • Merck & Co., Inc. • Eli Lilly and Company • Mylan N.V. • Teva Active Pharmaceuticals Industries Ltd. • Aurobindo Pharma • Sun Pharmaceutical Industries, Ltd. • Dr. Reddy’s Laboratories Ltd. • Albemarle Corporation Key Target Audience: • Healthcare companies • Corporate healthcare entities • Government agencies • Market research and consulting firms • Venture capitalists • Technical Students

Scope of the Active Pharmaceutical Ingredients Market Report:

The research report segments the active pharmaceutical ingredients market based on synthesis type, drug type, manufacturer type, therapeutic area, and geography.

Active Pharmaceutical Ingredients Market, By Synthesis Type

• Biotech • Monoclonal Antibodies • Recombinant Proteins • Vaccines • Synthetic

Active Pharmaceutical Ingredients Market, By Drug Type

• Branded Drugs • Generic Drugs • Over-the-counter (OTC) Drugs

Active Pharmaceutical Ingredients Market, By Manufacturer Type

• Captive Manufacturers • Merchant Manufacturers

Active Pharmaceutical Ingredients Market, By Therapeutic Area

• Cardiology • Pulmonology • Opthalmology • Neurology • Oncology • Orthopedics • Others

Active Pharmaceutical Ingredients Market, By Geography

• North America • U.S. • Canada • Europe • UK • Germany • France • Italy • Spain • Rest of Europe • Asia Pacific • Japan • China • India • Rest of Asia Pacific • Latin America • Brazil • Mexico • Rest of Latin America • MEA • South Africa • Saudi Arabia • Rest of MEA Geographic Analysis: • Breakdown of North America Active Pharmaceutical Ingredients Market • Breakdown of Europe Active Pharmaceutical Ingredients Market • Breakdown of Asia Pacific Active Pharmaceutical Ingredients Market • Breakdown of Latin America Active Pharmaceutical Ingredients Market • Breakdown of MEA Active Pharmaceutical Ingredients Market Available Customization: Maximize Market Research offers customization of reports according to the specific requirement of our clients.

Table of Contents

Active Pharmaceutical Ingredients Market

1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET VARIABLES & SCOPE 3.1. Market Segmentation & Scope 3.2. Market Driver Analysis 3.3. Market Restraint Analysis 3.4. Penetration & Growth Prospect Mapping 3.5. Market SWOT Analysis, By Factor (political & legal, economic, and technological) 3.6. Porter’s Five Forces Industry Analysis 3.7. Market Value Chain Analysis 4. SYNTHESIS TYPE ESTIMATES & TREND ANALYSIS (2019 – 2026) 4.1. Active Pharmaceutical Ingredients Market: Synthesis Type Movement Analysis 4.2. Biotech 4.2.1. Biotech market, 2019 – 2026 (USD billion) 4.2.2. Monoclonal antibodies 4.2.2.1. Monoclonal antibodies market, 2019 – 2026 (USD billion) 4.2.3. Recombinant proteins 4.2.3.1. Recombinant proteins market, 2019 – 2026 (USD billion) 4.2.4. Vaccines 4.2.4.1. Vaccines market, 2019 – 2026 (USD billion) 4.3. Synthetic 4.3.1. Synthetic market, 2019 – 2026 (USD billion) 5. DRUG TYPE ESTIMATES & TREND ANALYSIS (2019 – 2026) 5.1. Active Pharmaceutical Ingredients Market: Drug Type Movement Analysis 5.2. Branded/Innovative Drugs 5.2.1. Branded/Innovative drugs market, 2019 – 2026 (USD billion) 5.3. Generic Drugs 5.3.1. Generic drugs market, 2019 – 2026 (USD billion) 5.4. Over-the-counter (OTC) Drugs 5.4.1. Over-the-counter market, 2019 – 2026 (USD billion) 6. MANUFACTURER TYPE ESTIMATES & TREND ANALYSIS (2019 – 2026) 6.1. Active Pharmaceutical Ingredients Market: Manufacturer Type Movement Analysis 6.2. Captive Manufacturers 6.2.1. Captive manufacturers market, 2019 – 2026 (USD billion) 6.3. Merchant Manufacturers 6.3.1. Merchant manufacturers market, 2019 – 2026 (USD billion) 7. THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS (2019 – 2026) 7.1. Active Pharmaceutical Ingredients Market: Therapeutic Area Movement Analysis 7.2. Cardiology 7.2.1. Cardiology market, 2019 – 2026 (USD billion) 7.3. Pulmonology 7.3.1. Pulmonology market, 2019 – 2026 (USD billion) 7.4. Oncology 7.4.1. Oncology market, 2019 – 2026 (USD billion) 7.5. Neurology 7.5.1. Neurology market, 2019 – 2026 (USD billion) 7.6. Ophthalmology 7.6.1. Ophthalmology market, 2019 – 2026 (USD billion) 7.7. Orthopedics 7.7.1. Orthopedics market, 2019 – 2026 (USD billion) 7.8. Others 7.8.1. Others market, 2019 – 2026 (USD billion) 8. REGIONAL ESTIMATES & TREND ANALYSIS BY SYNTHESIS TYPE, DRUG TYPE, MANUFACTURER TYPE, THERAPEUTIC AREA, (2019 – 2026) 8.1. Active Pharmaceutical Ingredients Market Share By Region, 2019 & 2026 8.2. North America 8.2.1. North America active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.2.2. U.S. 8.2.2.1. U.S. active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.2.3. Canada 8.2.3.1. Canada active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3. Europe 8.3.1. Europe active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.2. UK 8.3.2.1. UK active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.3. Germany 8.3.3.1. Germany active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.4. France 8.3.4.1. France active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.5. Italy 8.3.5.1. Italy active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.6. Spain 8.3.6.1. Spain active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.7. Rest of Europe 8.3.7.1. Rest of Europe active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.4. Asia Pacific 8.4.1. Asia Pacific active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.4.2. Japan 8.4.2.1. Japan active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.4.3. China 8.4.3.1. China active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.4.4. India 8.4.4.1. India active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.4.5. Rest of Asia Pacific 8.4.5.1. Rest of Asia Pacific active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.5. Latin America 8.5.1. Latin America active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.5.2. Mexico 8.5.2.1. Mexico active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.5.3. Brazil 8.5.3.1. Brazil active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.5.4. Rest of Latin America 8.5.4.1. Rest of Latin America active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.6. MEA 8.6.1. MEA active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.6.2. South Africa 8.6.2.1. South Africa active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.6.3. Saudi Arabia 8.6.3.1. Saudi Arabia active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.6.4. Rest of MEA 8.6.4.1. Rest of active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 9. MARKET COMPETITION ANALYSIS 9.1. Strategy Framework 9.2. Company Profiles 9.2.1. AbbVie Inc. 9.2.1.1. Company Overview 9.2.1.2. Financial Performance 9.2.1.3. Product Benchmarking 9.2.1.4. Strategic Initiatives 9.2.2. Bristol-Myers Squibb Company 9.2.2.1. Company Overview 9.2.2.2. Financial Performance 9.2.2.3. Product Benchmarking 9.2.2.4. Strategic Initiatives 9.2.3. Boehringer Ingelheim GmbH 9.2.3.1. Company Overview 9.2.3.2. Financial Performance 9.2.3.3. Product Benchmarking 9.2.3.4. Strategic Initiatives 9.2.4. Cipla Inc. 9.2.4.1. Company Overview 9.2.4.2. Financial Performance 9.2.4.3. Product Benchmarking 9.2.4.4. Strategic Initiatives 9.2.5. Merck & Co., Inc. 9.2.5.1. Company Overview 9.2.5.2. Financial Performance 9.2.5.3. Product Benchmarking 9.2.5.4. Strategic Initiatives 9.2.6. Eli Lilly and Company 9.2.6.1. Company Overview 9.2.6.2. Financial Performance 9.2.6.3. Product Benchmarking 9.2.6.4. Strategic Initiatives 9.2.7. Mylan N.V. 9.2.7.1. Company Overview 9.2.7.2. Financial Performance 9.2.7.3. Product Benchmarking 9.2.7.4. Strategic Initiatives 9.2.8. Teva Active Pharmaceuticals Industries Ltd. 9.2.8.1. Company Overview 9.2.8.2. Financial Performance 9.2.8.3. Product Benchmarking 9.2.8.4. Strategic Initiatives 9.2.9. Aurobindo Pharma 9.2.9.1. Company Overview 9.2.9.2. Financial Performance 9.2.9.3. Product Benchmarking 9.2.9.4. Strategic Initiatives 9.2.10. Sun Pharmaceutical Industries, Ltd. 9.2.10.1. Company Overview 9.2.10.2. Financial Performance 9.2.10.3. Product Benchmarking 9.2.10.4. Strategic Initiatives 9.2.11. Dr. Reddy’s Laboratories Ltd. 9.2.11.1. Company Overview 9.2.11.2. Financial Performance 9.2.11.3. Product Benchmarking 9.2.11.4. Strategic Initiatives 9.2.12. Albemarle Corporation 9.2.12.1. Company Overview 9.2.12.2. Financial Performance 9.2.12.3. Product Benchmarking 9.2.12.4. Strategic Initiatives

About This Report

Report ID1816
Category Healthcare
Published DateJuly 2019
No of Pages196
Contact Us